Kymera Investor Presentation Deck
= Immunology-Inflammation
Clinical
Pipeline
Programs
with
DC/IND's
in 2023/24
Kymera's Pipeline of Novel Protein Degraders
KYMERA
Program
IRAK4
IRAKIMID
(IRAK4, Ikaros, Aiolos)
STAT3
MDM2
= Oncology
STAT3
Scaffolding Kinase
Transcription factor
IL4/13 Pathway
Transcriptional
Regulator
Novel Glue
Scaffolding Complex
Indication(s)
HS, AD, RA, others
MYD88MT Tumors
PTCL, LGL-L, CTCL,
Solid Tumors
Liquid & Solid Tumors
Autoimmune &
Fibrotic Diseases
Psoriasis, IBD, Lupus,
others
AD, Asthma, COPD,
EoE, PN
Lupus, Auto-Ab
Diseases, others
Ovarian, Breast
Ⓒ2023 KYMERA THERAPEUTICS, INC.
Discovery IND Enabling Phase 1
00
KT-474
KT-413
KT-333
KT-253
Phase 2
Next
Milestones
Ph2 Start 2023
Clinical Activity
2023
Clinical Activity
2023
POM 2023
Rights
KYMERA
sanofi
KYMERA
KYMERA
KYMERA
KYMERA
KYMERA
KYMERA
KYMERA
KYMERA
*
*Option to participate equally in the development and commercialization of Sanofi-partnered programs in the US
PAGE 7View entire presentation